- Home
- MFIN vs AMRN Comparison
MFIN vs AMRN Comparison
Compare MFIN & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$13.88
Company Overview
Basic Information| Metric | MFIN | AMRN |
|---|---|---|
| Founded | 1995 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.3M | 339.8M |
| IPO Year | 1996 | 1993 |
Fundamental Metrics
Financial Performance| Metric | MFIN | AMRN |
|---|---|---|
| Price | $10.80 | $13.88 |
| Analyst Decision | Strong Buy | Strong Sell |
| Analyst Count | 1 | 1 |
| Target Price | $12.00 | $12.00 |
| AVG Volume (30 Days) | 46.9K | ★ 84.3K |
| Earning Date | 10-29-2025 | 10-29-2025 |
| Dividend Yield | ★ 4.44% | N/A |
| EPS Growth | ★ 1.06 | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $338,783,000.00 | $226,733,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.83 | N/A |
| P/E Ratio | $6.33 | ★ N/A |
| Revenue Growth | ★ 15.53 | N/A |
| 52 Week Low | $7.71 | $7.08 |
| 52 Week High | $10.98 | $20.90 |
Technical Indicators
Market Signals| Indicator | MFIN | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 63.34 | 32.16 |
| Support Level | $10.35 | $13.64 |
| Resistance Level | $10.89 | $14.49 |
| Average True Range (ATR) | 0.30 | 0.76 |
| MACD | 0.06 | -0.11 |
| Stochastic Oscillator | 91.44 | 11.73 |
Price Performance
Historical Comparison MFIN
AMRN
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.